Team
The courses are a coproduction of
In Focus and Udenaes Consulting:
Margareta Hammarlund-Udenaes is Professor Emerita in Pharmacokinetics and Pharmacodynamics (PKPD) at Uppsala University and a former Dean of the Faculty of Pharmacy in Uppsala. Her research is focused at studying PK aspects of BBB transport of drugs in relation to CNS effects, which has led to the development of new concepts within the BBB transport area, focusing on unbound drug relationships. The concepts make it possible to study the BBB contribution to drug transport to the CNS. A method frequently used is microdialysis, but also PET and other techniques are utilized. Her research group has optimized in vitro methods for more rapid screening of BBB transport properties in drug discovery (Combinatory Mapping Approach). They also study nanodelivery to the brain. Dr Hammarlund-Udenaes has been an Associate Editor of Pharmaceutical Research and a member of the Editorial Advisory Board (EAB) several journals, currently being the Journal of Pharmaceutical Sciences, and on the EAB of Pharmaceutics. She became an AAPS Fellow in 2005 and is a frequent lecturer at conferences and in drug industry within the BBB transport – pharmacokinetics area. She co- founded and has co-chaired several of the International Symposia on Microdialysis in Drug Research and Development together with Dr de Lange, and was the Chair of the Gordon Conference on Barriers of the CNS in 2014.Her company Udenaes Consulting (udenaesconsulting@gmail.com) gives advice to drug industry in PKPD and BBB transport issues.
Elizabeth de Lange, PhD, is Professor of Predictive Pharmacology at the Division of Systems Biomedicine and Pharmacology of the LACDR. She focusses on the development of mathematical models to predict CNS PKPD relationships in human, in health and disease. This involves identification and characterization of key factors as well as their interdependencies. To that end she uses highly advanced and strategic in vivo preclinical experiments (including microdialysis), analysis of compounds in small samples, and mathematical modelling and simulation. She advocates comparative and integrative research designs to elucidate conditional influences of individual factors to the whole (Mastermind Research Approach), which is crucial for translation between species and conditions. A recent success is the development of the physiologically-based rat, human and mouse LeiCNSPK3.0 model that can adequately predict drug PK profiles in multiple compartments of the CNS. She co-founded and has co-chaired several of the International Symposia on Microdialysis in Drug Research and Development together with Dr Hammarlund-Udenaes, and organized many other scientific events (>100), and a frequently invited lecturer (>185). She has been on the EAB of several journals, and currently Pharmaceutical Research and Fluids and Barriers of the CNS. In Jan 2020, she received an Honorary doctorate in Pharmacy from Uppsala University. In Oct 2020 she received the Lewis Sheiner lecture award from the International Society of Pharmacometrics (ISoP). From 2020-2025 she was the scientific coordinantor of the H2020 EU consortium QSPainRelief (qspainRelief.eu) With her company In Focus she provides courses and training, and gives consults on (physiology-based) pharmacokinetics (PBPK), BBB transport, (CNS) target site distribution, binding kinetics and effects (PKPD) (ecmdelange@proton.me).